WEKO3
アイテム
{"_buckets": {"deposit": "f908d7dd-ec45-4436-a6cb-e18c46b6e9be"}, "_deposit": {"created_by": 11, "id": "3958", "owners": [11], "pid": {"revision_id": 0, "type": "depid", "value": "3958"}, "status": "published"}, "_oai": {"id": "oai:shiga-med.repo.nii.ac.jp:00003958", "sets": ["193"]}, "author_link": ["3728", "8586", "7780", "8585", "8587", "7773"], "item_4_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2021-07-20", "bibliographicIssueDateType": "Issued"}, "bibliographic_titles": [{}, {"bibliographic_title": "Graefe\u0027s Archive for Clinical and Experimental Ophthalmology", "bibliographic_titleLang": "en"}]}]}, "item_4_creator_3": {"attribute_name": "著者別名", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "大路, 正人"}], "nameIdentifiers": [{"nameIdentifier": "3728", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "90252650 ", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=90252650 "}]}]}, "item_4_description_14": {"attribute_name": "フォーマット", "attribute_value_mlt": [{"subitem_description": "pdf", "subitem_description_type": "Other"}]}, "item_4_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Purpose:\nTo explore the relationship between retinal fluid status and best-corrected visual acuity (BCVA) in patients treated with intravitreal aflibercept (IVT-AFL) treat-and-extend (T\u0026E) in the ALTAIR study. ", "subitem_description_type": "Abstract"}, {"subitem_description": "Methods:\nOutcomes were investigated according to overall fluid status at week 16 (predefined) and the relationship between any fluid, intraretinal fluid (IRF), subretinal fluid (SRF), or pigment epithelial detachment with BCVA at baseline, and weeks 16, 52, and 96 (post-hoc). The analyses involved treatment-naïve patients (N = 246) with exudative age-related macular degeneration (AMD), aged ≥ 50 years with BCVA of 73-25 Early Treatment Diabetic Retinopathy Study letters, who participated in the ALTAIR study. ", "subitem_description_type": "Abstract"}, {"subitem_description": "Results:\nThe mean (standard deviation) change in BCVA from baseline to week 52 was + 10.6 (10.9) and + 6.5 (16.0) letters in patients without and with fluid at week 16, respectively; and to week 96 was + 9.1 (14.3) and + 4.3 (16.1) letters in patients without and with fluid at week 16, respectively. The last injection interval was 16 weeks in 33.6% and 2.0% (week 52), and 62.9% and 17.6% (week 96) of patients without or with fluid at week 16, respectively. At baseline, 35.7% of patients had IRF and 85.2% of patients had SRF, which decreased to 11.8% (IRF) and 31.7% (SRF) of patients, 8.5% (IRF) and 18.7% (SRF), and 6.5% (IRF) and 20.7% (SRF) at weeks 16, 52, and 96, respectively. Presence of IRF at all timepoints was associated with poorer BCVA than if IRF was absent, while the presence of SRF was not associated with poorer BCVA compared with the absence of SRF. ", "subitem_description_type": "Abstract"}, {"subitem_description": "Conclusion:\nIVT-AFL T\u0026E dosing was effective at clearing fluid regardless of fluid type in ~ 80% of patients with exudative AMD. Patients without fluid at week 16 had numerically better BCVA than those with fluid at week 16. Over 60% of patients without fluid at week 16 achieved the maximum treatment interval of 16 weeks by study end, compared with \u003c 20% of patients with fluid at week 16. IRF (weeks 16, 52, 96), although evident in a small number of patients, was associated with poorer BCVA, whereas SRF was not. ", "subitem_description_type": "Abstract"}, {"subitem_description": "Trial registration: ClinicalTrials.gov Identifier: NCT02305238. (http://clinicaltrials.gov/show/NCT02305238)", "subitem_description_type": "Abstract"}]}, "item_4_description_42": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"subitem_description": "Journal Article", "subitem_description_type": "Other"}]}, "item_4_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Springer Science and Business Media Deutschland GmbH"}]}, "item_4_relation_10": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "34283294", "subitem_relation_type_select": "PMID"}}]}, "item_4_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1007/s00417-021-05293-y"}], "subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1007/s00417-021-05293-y", "subitem_relation_type_select": "DOI"}}]}, "item_4_relation_48": {"attribute_name": "関係URI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "Erratum in"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://hdl.handle.net/10422/00013281", "subitem_relation_type_select": "HDL"}}]}, "item_4_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2021. The Author(s). "}]}, "item_4_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0721-832X", "subitem_source_identifier_type": "ISSN"}]}, "item_4_version_type_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "OHJI, Masahito"}], "nameIdentifiers": [{"nameIdentifier": "3728", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "90252650 ", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=90252650 "}]}, {"creatorNames": [{"creatorName": "OKADA, Annabelle Ayame"}], "nameIdentifiers": [{"nameIdentifier": "7773", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "SASAKI, Koji"}], "nameIdentifiers": [{"nameIdentifier": "8585", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "MOON , SungChul Charles"}], "nameIdentifiers": [{"nameIdentifier": "8586", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "MACHEWITZ, Tobias"}], "nameIdentifiers": [{"nameIdentifier": "8587", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "TAKAHASHI, Kanji"}], "nameIdentifiers": [{"nameIdentifier": "7780", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-08-12"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "s00417-021-05293-y.pdf", "filesize": [{"value": "991.5 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensefree": " This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article\u0027s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article\u0027s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit \nhttp://creativecommons.org/licenses/by/4.0/.", "licensetype": "license_free", "mimetype": "application/pdf", "size": 991500.0, "url": {"label": "s00417-021-05293-y", "url": "https://shiga-med.repo.nii.ac.jp/record/3958/files/s00417-021-05293-y.pdf"}, "version_id": "62293dc4-4d17-4146-ba17-4126aa73f77c"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Aflibercept", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Exudative age-related macular degeneration", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Ophthalmology", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Post-hoc", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Treat-and-extend", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study."}]}, "item_type_id": "4", "owner": "11", "path": ["193"], "permalink_uri": "http://hdl.handle.net/10422/00013056", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-08-12"}, "publish_date": "2021-08-12", "publish_status": "0", "recid": "3958", "relation": {}, "relation_version_is_last": true, "title": ["Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study."], "weko_shared_id": -1}
Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study.
http://hdl.handle.net/10422/00013056
http://hdl.handle.net/10422/0001305697b9b490-6807-4993-b8b4-18d4e2b02033
名前 / ファイル | ライセンス | アクション |
---|---|---|
s00417-021-05293-y (991.5 kB)
|
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. |
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-08-12 | |||||
タイトル | ||||||
タイトル | Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study. | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Aflibercept | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Exudative age-related macular degeneration | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Ophthalmology | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Post-hoc | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Treat-and-extend | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
OHJI, Masahito
× OHJI, Masahito× OKADA, Annabelle Ayame× SASAKI, Koji× MOON , SungChul Charles× MACHEWITZ, Tobias× TAKAHASHI, Kanji |
|||||
著者別名 |
大路, 正人
× 大路, 正人 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Purpose: To explore the relationship between retinal fluid status and best-corrected visual acuity (BCVA) in patients treated with intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E) in the ALTAIR study. |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Methods: Outcomes were investigated according to overall fluid status at week 16 (predefined) and the relationship between any fluid, intraretinal fluid (IRF), subretinal fluid (SRF), or pigment epithelial detachment with BCVA at baseline, and weeks 16, 52, and 96 (post-hoc). The analyses involved treatment-naïve patients (N = 246) with exudative age-related macular degeneration (AMD), aged ≥ 50 years with BCVA of 73-25 Early Treatment Diabetic Retinopathy Study letters, who participated in the ALTAIR study. |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Results: The mean (standard deviation) change in BCVA from baseline to week 52 was + 10.6 (10.9) and + 6.5 (16.0) letters in patients without and with fluid at week 16, respectively; and to week 96 was + 9.1 (14.3) and + 4.3 (16.1) letters in patients without and with fluid at week 16, respectively. The last injection interval was 16 weeks in 33.6% and 2.0% (week 52), and 62.9% and 17.6% (week 96) of patients without or with fluid at week 16, respectively. At baseline, 35.7% of patients had IRF and 85.2% of patients had SRF, which decreased to 11.8% (IRF) and 31.7% (SRF) of patients, 8.5% (IRF) and 18.7% (SRF), and 6.5% (IRF) and 20.7% (SRF) at weeks 16, 52, and 96, respectively. Presence of IRF at all timepoints was associated with poorer BCVA than if IRF was absent, while the presence of SRF was not associated with poorer BCVA compared with the absence of SRF. |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Conclusion: IVT-AFL T&E dosing was effective at clearing fluid regardless of fluid type in ~ 80% of patients with exudative AMD. Patients without fluid at week 16 had numerically better BCVA than those with fluid at week 16. Over 60% of patients without fluid at week 16 achieved the maximum treatment interval of 16 weeks by study end, compared with < 20% of patients with fluid at week 16. IRF (weeks 16, 52, 96), although evident in a small number of patients, was associated with poorer BCVA, whereas SRF was not. |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Trial registration: ClinicalTrials.gov Identifier: NCT02305238. (http://clinicaltrials.gov/show/NCT02305238) | |||||
書誌情報 |
en : Graefe's Archive for Clinical and Experimental Ophthalmology 発行日 2021-07-20 |
|||||
出版者 | ||||||
出版者 | Springer Science and Business Media Deutschland GmbH | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0721-832X | |||||
PMID | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | PMID | |||||
関連識別子 | 34283294 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1007/s00417-021-05293-y | |||||
関連名称 | 10.1007/s00417-021-05293-y | |||||
権利 | ||||||
権利情報 | © 2021. The Author(s). | |||||
フォーマット | ||||||
内容記述タイプ | Other | |||||
内容記述 | ||||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
資源タイプ | ||||||
内容記述タイプ | Other | |||||
内容記述 | Journal Article | |||||
関係URI | ||||||
識別子タイプ | HDL | |||||
関連識別子 | http://hdl.handle.net/10422/00013281 | |||||
関連名称 | Erratum in |